Depo-Provera Settlement Calculator 2026: What Real Depo-Provera Cases Have Paid

Who May Qualify for a Depo-Provera Lawsuit Review?

Eligibility is not determined by this page. Attorneys evaluating a potential claim may review the type and duration of medroxyprogesterone acetate injections, diagnosis timing, tumor type and location, treatment, medical proof, alternative risk factors, damages, defendants and applicable filing deadline.

What the 2026 Depo-Provera Master Settlement Actually Is

A master settlement agreement is not a payout schedule, and the difference decides what this page can honestly tell you. Pfizer and plaintiffs’ leadership announced a global agreement in principle on June 15, 2026, and Judge M. Casey Rodgers vacated the first bellwether trial, Toney v. Pfizer, which had been set for December 7, 2026. The master agreement itself was signed on July 21, 2026 and covers most of the federal claims then on file in MDL 3140, with the parties estimating that roughly 80 percent of MDL plaintiffs will meet the eligibility criteria. BrownGreer PLC was appointed settlement administrator on August 5, 2026. Every one of those steps is real, dated and checkable — and not one of them is a dollar figure.

The terms of the agreement are confidential. There is no public payout chart, no per-tier compensation range and no total fund size confirmed by the court or by either party. That is an ordinary feature of a private aggregate settlement: the parties negotiate a framework, a third-party administrator evaluates each claim against agreed criteria, and individual offers go to individual claimants rather than to the docket. It also means that any specific Depo-Provera settlement amount circulating online right now — and several are circulating, usually as a range spanning an order of magnitude — has no basis in any filed document. This page does not repeat them, and a reader who finds one elsewhere is entitled to ask which record it came from.

What the settlement does not do matters as much as what it does. The court noted that the agreement will not end the MDL: only plaintiffs who meet the eligibility criteria agreed by the parties will have the opportunity to resolve their claims, so a claim that falls outside those criteria stays in litigation on the ordinary track. Pfizer’s federal preemption motion was still undecided when the agreement was reached, which is unusually early in a pharmaceutical MDL and is part of why the terms carry the conditions they do. Registration for the programme is expected to open and complete during November 2026, with the first payments projected for the first quarter of 2027 — projected by the administrator’s timetable, not guaranteed by any order.

For a claimant, the practical work is the same as it was before the agreement: the injection records establishing how long Depo-Provera or its generic equivalent was used, the imaging and pathology confirming an intracranial meningioma, and the dates linking the two. Those are the documents an administrator evaluates, and they are what the calculator on this page organises. Our Depo-Provera lawsuit guide covers who may qualify and on what theories, the Depo-Provera settlement amounts page records the money question as it develops, and our 2026 settlement update tracks each filing as it lands.

Evidence That Can Strengthen a Depo-Provera Claim Review

The calculator is most useful when answers can be tied to records rather than estimates from memory.

• Depo-Provera injection records and dates
• Pharmacy, OB-GYN, clinic or insurer records confirming use
• MRI or CT imaging confirming the meningioma
• Pathology, neurology, oncology or neurosurgery records
• Craniotomy, radiation and hospitalization records
• Records of seizures, vision loss, hearing changes, headaches or cognitive effects
• Medical bills and out-of-pocket expenses
• Lost-income and employment documentation
• Disability, caregiving and rehabilitation records
• Future-treatment or surveillance recommendations
• A dated injection-to-diagnosis timeline
• Documents showing the impact on normal activities and work

How the Depo-Provera Settlement Calculator Works

The calculator organizes claim information into a preliminary educational model. It does not use one universal multiplier or substitute for medical, legal or records review.

Related Depo-Provera & Settlement Resources

How We Sourced This Page

Every fact on this page is dated to the event that produced it. The June 15, 2026 agreement in principle and the vacatur of the Toney bellwether come from Judge Rodgers’s order in MDL 3140; the July 21, 2026 master settlement agreement, the roughly 80 percent eligibility estimate and BrownGreer’s August 5, 2026 appointment as administrator come from the reporting of that docket. The pending-case count comes from the Judicial Panel on Multidistrict Litigation’s own September 1, 2026 statistics report. Where the page describes what the medical literature shows about medroxyprogesterone acetate and intracranial meningioma, it links the peer-reviewed study rather than a summary of it, and where it describes the label, it links the FDA record.

This page publishes no settlement range, no average and no claim tier for Depo-Provera, because the master settlement agreement is confidential and no payout schedule has been filed or released. Ranges quoted elsewhere are attorney estimates, and an estimate offered before an administrator has evaluated a single claim is a guess with a dollar sign in front of it. Where this page states that something is projected — the November 2026 registration window, the first-quarter 2027 payment timetable — it says who is projecting it. Facts were re-read against their sources on September 12, 2026. The same standard governs the other TortAdvisor settlement calculators and the settlement amounts library.

Depo-Provera Litigation, FDA & Medical Sources